OpenCapitalBeta

Calendar Stocks Metrics

/

Stocks
Royalty Pharma
Business Segments
Products & Services
Research and development funding expense

Research and development funding expense

Royalty Pharma·Products & Services·1 segment·Rolls up to R&D

Breakdown

Segments

Phase 2b, TEV-408View metric

Navigation

Earnings Calendar
Stocks
Pricing
About
Methodology

Connect

Claude (MCP)
ChatGPT (MCP)
Portfolio (Plaid)

Legal

Privacy Policy
Terms of Service
Cookie Policy
SEC EDGAR
support@opencapital.sh

© 2026 OpenCapital. All rights reserved.

Data sourced from SEC filings — methodology

OpenCapital is not affiliated with or endorsed by the U.S. Securities and Exchange Commission (SEC). All data is sourced from publicly available SEC filings.

OpenCapital

Segment	Q1 '26
Phase 2b, TEV-408	$14.30M
Total	$39.79M